Search
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalApart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. … Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action.
Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16713ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 8 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16715ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 11A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 9N capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19342ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae_ serotype 9N individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 15A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19343ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae_ serotype 15A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 17F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19346ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae_ serotype 17F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19347ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae_ serotype 20A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptomycin
go.drugbank.com/drugs/DB01082ApprovedInvestigationalVet approvedStreptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965]. … Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).